On February 26th PEPAXTO (melphalan flufenamide) in combination with dexamethason was granted accelerated approval by the U.S. Food and Drug Administration, FDA, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Following the approval PEPAXTO has been included in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network® (NCCN) in Oncology, in the US.
Melflufen is the first drug candidate coming out of the company´s proprietary Peptide Drug Conjugate platform, PDC. Oncopeptides is developing several new compounds based on the PDC platform. The second compound from the PDC platform, OPD5, is ready to enter clinical development.
Oncopeptides has a facility for pre-clinical drug development in Solna, Sweden, which provides adequate resources to further expand the development of the PDC-platform and generate new drug candidates.
Footprint in leading biotech hubs
The global headquarters is in Stockholm, Sweden, and the U.S. headquarters in Waltham, Massachusetts, outside of Boston. In addition, the company has an office in Los Altos, California, outside of San Francisco. We also have a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.
Oncopeptides AB (publ) has approximately 300 coworkers and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.